First Human Trial: Low-Dose Mitragynine Improves Attention; High Doses Trigger Memory Impairment

Why it matters

This rare human controlled trial fills a critical gap: most kratom safety data comes from animal studies or case reports. Understanding mitragynine's dose-dependent cognitive effects is essential for patient counseling and future clinical development.

The big picture

Research on kratom's effects in humans has been severely limited by regulatory barriers and lack of funding. Most pharmacological data has come from animal models or retrospective user surveys. Maastricht University's neuropsychopharmacology group, one of Europe's most prominent in human drug research, conducted this exploratory trial using controlled oral mitragynine doses to assess both safety and cognitive performance across dose levels.

Key findings

• Healthy participants received single oral doses of mitragynine at 6 mg, 12 mg, 24 mg, or placebo in a double-blind crossover design
• Low doses (6 mg) produced modest improvements in sustained attention and response speed
• At 24 mg, participants showed significant impairment in memory encoding and recall — a dissociative amnesia-like effect
• Vital signs remained within normal ranges across all doses; no serious adverse events were observed
• The study confirmed dose-dependent pharmacokinetics, with peak plasma levels at approximately 2 hours post-dose

What they say

The authors concluded: "These findings suggest that mitragynine has a biphasic dose-dependent effect on neurocognition, with stimulant-like effects at low doses and sedative/amnestic effects at higher doses — a pattern consistent with its opioid and adrenergic receptor activity."

Bottom line

The first placebo-controlled human trial of mitragynine finds a clear dose-response curve: alerting at low doses, impairing memory at high doses — echoing what kratom users have long reported anecdotally.